Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03331861 · ClinicalTrials.gov registry record · Phase 2

Metformin in Heart Failure Without Diabetes

A Phase 2 study, sponsored by Columbia University.

Terminated
Registry status
Phase 2
Development phase
6
Enrollment target

NCT03331861 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03331861, a Phase 2 study, was terminated before completion, sponsored by Columbia University.

TERMINATED
Registry status
Phase 2
Development phase
6 participants
Enrollment target

Study Summary

A pilot clinical research study that will assess the use of the medication metformin for heart failure in patients who are not diabetic and have no evidence of insulin resistance.

Interventions

  • DRUG Placebo
  • DRUG Metformin hydrochloride

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2019-02-15
Est. Completion 2021-08-20
Phase Phase 2

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT03331861

The ClinicalTrials.gov registry entry for NCT03331861 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03331861 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03331861 about?

NCT03331861 is a clinical study titled "Metformin in Heart Failure Without Diabetes". A pilot clinical research study that will assess the use of the medication metformin for heart failure in patients who are not diabetic and have no evidence of insulin resistance.

What is the current status of trial NCT03331861?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-02-15. Estimated completion is 2021-08-20.

What interventions are being tested in trial NCT03331861?

The interventions under investigation include: Placebo (DRUG), Metformin hydrochloride (DRUG).

Who is sponsoring clinical trial NCT03331861?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.